iQure Pharma Attending JPM Week in San Francisco — January 12-16, 2024
December 10, 2025 – Princeton, NJ – iQure Pharma, a clinical-stage biotech company breaking the cycle of excitotoxicity by restoring glutamate balance to treat CNS disorders, today announced that members of its management team will attend the 43rd Annual J.P. Morgan Health Care Conference (JPM Week) taking place January 12–16, 2025, in San Francisco, California.
iQure Pharma’s leadership team, including Pawel Zolnierczyk, Chief Executive Officer, and Henk de Wilde, Chief Operating Officer and Chief Development Officer, will participate in Biotech Showcase and BIO Partnering @JPM to engage with potential partners and investors as the company advances its clinical pipeline.
The company’s lead asset, iQ-007, is a first-in-class small molecule designed to enhance the function of EAAT2, the primary astrocytic transporter responsible for clearing excess synaptic glutamate. iQ-007 is currently in Phase 1 clinical development, with potential indications in drug-resistant epilepsy, migraine, and neurodegeneration.
“JPM Week is an important moment to continue our discussions with partners interested in new approaches to restoring glutamate homeostasis,” said Pawel Zolnierczyk, CEO of iQure Pharma. “Our focus remains on advancing iQ-007 toward Phase 2 and expanding the scientific and clinical foundation for EAAT2-based therapies across CNS disorders.”
Companies and investors interested in meeting the iQure team are encouraged to request a meeting through the official partnering platforms or contact the company directly at info@iqurepharma.com.
About iQure Pharma
iQure is a clinical-stage biotech company advancing a new therapeutic approach for CNS disorders by restoring glutamate homeostasis.
Our science targets one of the core functions of astrocytes: the regulation of glutamate uptake, essential for maintaining synaptic balance and protecting neurons from overstimulation. By enhancing the function of the main transporter involved in this process, we break the cycle of excitotoxicity, a feedback loop that drives neuronal damage and disease progression across a broad range of CNS conditions.
Our lead asset, iQ-007, is a first-in-class, orally available small molecule that enhances the activity of the main glutamate transporter. Currently in Phase 1 clinical development for treatment-resistant epilepsy, iQ-007 provides the first clinical validation of our approach. Beyond epilepsy, we are advancing additional preclinical programs targeting neurodegeneration and pain. For more information visit www.iqurepharma.com.
Media Contact
Clara Assouline
Business Development, iQure Pharma
clara.assouline@iqurepharma.com
www.iqurepharma.com
